Traphaco and its 5 consecutive times in Top 50 best listed companies in Vietnam  2017

On Sep 14th 2017, at the GEM Center, Forbes Vietnam - the well-known worldwide magazine on business has announced and honored the 50 best listed companies in Vietnam. This is the 5th Forbes Vietnam to announce the list and also the 5th Traphaco was honored in the Top 50 Best Companies Listed. Traphaco is one of two representatives of the pharmaceutical industry on the list.

According to the Judging Council, the chosen companies include those in 13 sectors ranging from real estate and construction, technology, multi-sector, oil & gas, finance, consumer goods, materials, industry to agriculture, pharmaceuticals and transport. They all have great influence in the market and enjoyed outstanding business results over the past year. 

In particular, Forbes looks at all listed shares on HSX and HNX and sorts their companies in respective industry. In the preliminary round, companies that are at loss, once delisted, have a capitalization value and turnover less than 300 billion dong, or have dependent subsidiaries are all out. In the quantitative round, companies were rated according to this criteria: CAGR in revenue, profitability, ROE, ROC and EPS growth for 2012-2016. The quantitative calculation in this round is supported by the Ban Viet Securities Company.

Next, in the qualitative round, Forbes Vietnam assessed the sustainable development of the enterprises: brand-name, corporate governance quality, past profit origins, and sustainable development prospects. Companies with repeated violation of the disclosure obligations of two stock exchanges and in doubt over manipulation of stock prices were eliminated.

Traphaco is known as the leading company in herbal and traditional pharmaceuticals, with two signature products: Boganic and Cebraton.  These two products ranked respectively second and sixth in the Top 20 best-sold OTC pharmaceuticals in the market.

From the fifth place, Traphaco has risen strongly to the second place in terms of revenue and profit. Over the past five years, Traphaco has made a miracle with its revenue has doubled, its profit tripled, its market capitalization quadrupled.

In the development strategy for the period of 2017-2020, Traphaco aims to become the No. 1 pharmaceutical company in Vietnam in terms of revenue growth, profitability and market capitalization. By 2020, its market capitalization is targeted at VND 10 trillion, total revenue at VND 4 trillion, profits at VND 500 billion.

To this end, Traphaco will continue to focus on the domestic market and make a breakthrough in the South by diversifying its products and optimizing its comparative advantages. The company will also modernize the supply chain with the latest technology and advanced management systems. At the same time, commercial alliances and partnership supported by a broad, deep and solid distribution system will be further developed. In this year, Traphaco has invested in a modern pharmaceutical factory with a total investment capital of 500 billion VND, aiming for high standards like GMP-EU. Traphaco has also applied ERP since 2017, expanding the application of information technology, step by step building "digital business". These are solid foundation for Traphaco’s firm steps into the future.